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Abstract
Background: Adipose-derived stem cells (ASCs) are mesenchymal stem cells (MSCs) derived from adipose tissue.
MSCs have multiple properties including anti-inflammatory and immunomodulatory effects in various disease
models and human diseases. However, the mechanisms underlying this wide range of effects need to be explored.
Methods: Collagen antibody-induced arthritis (CAIA) is a unique model in which arthritis is rapidly and strongly
induced. ASCs were intraperitoneally infused into CAIA mice before or after arthritis induction. The serum levels of
various cytokines, adipokines, and chemokines were measured. The expression of FC gamma receptors (FCGRs) was
investigated in peritoneal macrophages ex vivo. RAW264.7 cells and ASCs were co-cultured to elucidate the direct and
indirect role of ASCs on FCGR expression.
Results: ASCs attenuated arthritis in CAIA mice. Serum levels of tumor necrosis factor α, interleukin (IL)-15, resistin, and
leptin were reduced in ASC-treated CAIA mice, whereas serum levels of IL-6 and adiponectin were not affected. In
peritoneal macrophages isolated from ASC-treated mice, expression of FCGRIIB, which is immunoinhibitory, was higher
than that of FCGRI. Co-culture of ASCs with RAW264.7 cells modulated the expression of FCGRs. The expression
patterns and timings of peak expression differed among FCGRs. Expression of FCGRIIB was higher and peaked earlier
than that of FCGRI. FCGRIII expression was not affected by this co-culture.
Conclusions: This is a study to show that ASCs have anti-arthritic effects in CAIA mice. Modulation of FCGRs by ASCs
might be a therapeutic mechanism in this antibody-associated arthritis model.
Keywords: Adipose-derived stem cell, Mesenchymal stem cell, Collagen antibody-induced arthritis, FC gamma
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Background
Mesenchymal stem cells (MSCs) are cells of a stromal
origin that can self-renew and differentiate into various
lineages of mesenchymal tissues. Furthermore, MSCs exert
profound immunosuppressive effects that are superior to
those of all other immunosuppressive cell types [1]. The ef-
fects of MSCs on immune cells have mostly been studied
using bone marrow-derived MSCs (BM-MSCs). BM-MSCs
have widespread effects on innate and adaptive immune
cells [2]. BM-MSCs can inhibit CD4+ T-cell prolifera-
tion and B-cell differentiation and induce the differenti-
ation of regulatory T-cells (T-reg) [1, 3–5]. In relation
to innate immune cells, BM-MSCs suppress the gener-
ation of dendritic cells from monocytes [6], reduce the
expression of CD80 and CD86 co-stimulatory mole-
cules on antigen-presenting cells (APCs), and reduce
the production of pro-inflammatory cytokines, such as
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interleukin (IL)-2, interferon-γ, and tumor necrosis fac-
tor α (TNFα), by APCs [7].
Adipose-derived MSCs (ASCs) and BM-MSCs can both
differentiate toward multiple mesodermal tissue types, in-
cluding bone, cartilage, and adipose tissue, are both im-
munosuppressive, and have similar surface protein marker
expression [8–11]. However, ASCs senesce later than
BM-MSCs, which may be beneficial for the treatment
of chronic or persistent conditions. ASCs have a multi-
lineage differentiation capacity and elicit immunosup-
pressive effects on activated immune cells [12, 13].
ASCs release growth factors that are important for
wound healing, modulate the immune system, decrease
inflammation, and home to injured tissues [14]. ASCs
may be of great clinical utility in regenerative therapies
for Parkinson’s disease, Alzheimer’s disease, spinal cord
injury, heart diseases, and rheumatoid arthritis (RA).
The immunosuppressive effects of ASCs are well
known. In vitro, ASCs inhibit the proliferation of acti-
vated lymphocytes via cell-cell binding and paracrine
signaling [15]. Expanded ASCs have immunosuppressive
properties in mice, thereby alleviating graft-versus-host-
disease and colitis [16, 17]. ASCs also have anti-
inflammatory effects via inducing immune tolerance in a
RA mouse model, namely, type II collagen-induced arth-
ritis (CIA) mice [16]. The immunosuppressive effects of
ASCs in CIA were explained by Th1/Th17 suppression
and T-reg induction [16, 18].
RA involves a multicellular inflammatory process, in-
cluding the infiltration of lymphocytes and granulocytes
into articular cartilage, proliferation of synovial fibro-
blasts and macrophages, and neovascularization of the
synovial lining of joints. Many cellular components (macro-
phages, dendritic cells, neutrophils, T-cells, and B-cells), cell
surface molecules, signaling components, and humoral
components interact and aid the progression of RA [19].
CIA is the most commonly used arthritis model and is in-
duced by type II collagen treatment. Collagen antibody-
induced arthritis (CAIA; induced by anti-type II collagen
antibodies (anti-COL II)) is another widely used mouse
model [20]. The actions of anti-collagen antibodies are initi-
ated by direct binding to their antigens and involve immune
complex formation, immune complex deposition, and acti-
vation of complement and Fc receptors [19]. Type II
collagen-specific antibodies induce arthritis in the absence
of T- and B-cells [21]; therefore, CAIA is considered to be a
T-cell- and B-cell-independent arthritis model, in contrast
to CIA. The suppressive effects of ASCs on arthritis are re-
lated to the T-cell balance in CIA mice, and the effects of
ASCs on other immune cells, aside from T-cells, have not
been investigated.
This study investigated the effects of human ASCs
on autoimmune arthritis in CAIA mice, which is not
related to the T-cell immune response, and analyzed




All procedures involving animals were in accordance
with the Laboratory Animals Welfare Act, the Guide for
the Care and Use of Laboratory Animals, and the Guide-
lines and Policies for Rodent Experimentation provided
by the Institutional Animal Care and Use Committee of
the School of Medicine of The Catholic University of
Korea. The study protocol was approved by the Institu-
tional Review Board of The Catholic University of Korea
(CUMC-2012-0033-01). Female DBA1/J mice (7-week-
old; OrientBio, Korea) were purchased and housed in
specific pathogen-free conditions under approved insti-
tutional guidance.
Induction of CAIA and injection of ASCs
Seven-week-old female DBA1/J mice (five mice per group)
were intravenously injected with anti-CII (2 mg; Chon-
drex, WA, USA). After 3 days, 50 μg of lipopolysaccharide
(LPS; Chondrex) was administered intraperitoneally to
mice. As a control, the same volumes of normal saline
were injected into wild-type mice instead of anti-CII and
LPS (WT group). For the ASC-pre-injected group (ASC
pre), 1 × 107 cells/mouse (in 500 μl of saline) were injected
intravenously three times every other day starting 3 days
prior to immunization with anti-CII. For the ASC-post-
injected group (ASC post), ASCs were injected identically
starting 4 days after immunization with anti-CII.
Evaluation of disease severity
The incidence and severity of arthritis were monitored
and scored as described previously [22]. The incidence
was calculated as the percentage of mice in which one
or more paws were swollen.
Histological evaluation of arthritis
Mice were sacrificed 14 days after immunization with
anti-CII. A hind limb of each mouse was removed and
fixed in 10 % formalin. After decalcification in 10 % (w/
v) EDTA, the samples were embedded in paraffin. The
4 μm-thick sections were stained with hematoxylin and
eosin (H&E) or toluidine blue. The inflammation score
and joint destruction score were determined. Briefly, the
presence of synovial hyperplasia and leukocyte infiltra-
tion in H&E-stained samples were graded in a blinded
fashion by three independent observers; the sum of the
two values was used as the inflammation score. The
presence of pannus formation and cartilage erosion were
scored and the sum of the two scores was used as the
joint destruction score.
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Assessment of serum levels of cytokines and hormones
Venous blood (300 μl) was obtained from mice on the
day of sacrifice. Blood samples were incubated at room
temperature and then centrifuged for 10 min at 4 °C to
obtain serum. Serum samples were used to assess cyto-
kines and hormones. Resistin, gastric inhibitory polypep-
tide (GIP), glucagon-like peptide 1 (GLP-1), ghrelin,
leptin, IL-15, IL-1α, IL-6, IL-7, TNFα, and adiponectin
were analyzed using Procarta kits from Affymetrix (Fre-
mont, CA, USA) according to the manufacturer’s proto-
cols. All specimens were assayed in triplicate. Multiplex
immunoassays were performed using the Luminex 100 IS
System (Luminex Corp., Austin, TX, USA). Sample con-
centrations were calculated from standard curves using
Bio-Plex Manager 4.1.1 (Bio-Rad Laboratories, Hercules,
CA, USA).
Cells
The murine macrophage cell line RAW264.7 was cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco) supplemented with 10 % fetal bovine serum
(FBS; Gibco) and 1 % penicillin/streptomycin solution
(P/S solution; Gibco). ASCs (passage 2–3) were pur-
chased from Catholic MASTER Cells (Seoul, Korea) and
maintained in DMEM supplemented with 10 % FBS and
1 % P/S solution.
Isolation of peritoneal cells
Five milliliters of phosphate-buffered saline containing
3 % FBS was injected per mouse into the peritoneal cav-
ity using a 10-ml syringe. After gentle massage, the peri-
toneal fluid was collected using the same syringe and
centrifuged at 1500 × g for 5 min. The isolated cells were
used for RNA purification.
Reverse-transcription PCR
Total RNA was purified from cells using TRIzol reagent
(Invitrogen) following the manufacturer’s instruction. A
Revertaid™ First Stranded cDNA Synthesis Kit (Fermen-
tas) was used to synthesize cDNA from RNA. PCR was
performed using an iTaq DNA Polymerase Kit (iNtRON
biotechnology) following the manufacturer’s guidelines.
The primer sequences used for PCR are as follows: 5’-
TGCGGAACCAGAGCAGGGGT-3’ and 5’- TTTGGGC
CAGTGTTCCCGCC-3’ for FCGRI (NM_010186.5), 5’-
TGGGAGGTCCATCCGGAGCC-3’ and 5’- TCAGGAG




3’ and 5’-GACACATTGGGGGTAGGAAC-3’ for GAPDH
(NM_008084.2).
Statistical analysis
Statistical analysis was performed using Student’s t-test.
p < 0.05 was considered significant.
Results
ASCs ameliorate arthritis in CAIA mice
To investigate the effects of ASCs on CAIA, 1 × 107 ASCs
were injected three times into CAIA mice. The timing of
ASC injection might be important; therefore, we divided
ASC-injected mice into two groups: ASC pre and ASC
post. In the ASC pre group, ASCs were injected before
arthritis symptoms arose. In the ASC post group, ASCs
were injected after LPS boosting. Both ASC-injected
groups had an ameliorated disease severity score and ex-
hibited delayed disease incidence (Fig. 1a and b).
Fig. 1 Injection of adipose-derived mesenchymal stem cells (ASCs) ameliorates arthritis in collagen antibody-induced arthritis (CAIA) mice. CAIA mice
were injected with ASCs three times every other day starting 3 days prior to (ASC pre group) or 4 days after (ASC post group) immunization with an
anti-collagen type II antibody. As controls, wild-type mice were injected with saline (WT group) and CAIA mice were similarly immunized but not
injected with ASCs (CAIA group). Each group comprised 5 mice. The disease severity score (a, mean ± standard error of the mean) and incidence of
arthritis (b) were calculated at various numbers of days following immunization
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ASCs prevent inflammation and bone destruction
The effects of ASCs were examined histologically by
H&E and toluidine blue staining (Fig. 2a). The histo-
logical inflammation and bony destruction scores were
lower in the ASC-injected groups than in control CAIA
mice (Fig. 2b and c). TRAP staining showed that multi-
nucleated TRAP-positive osteoclasts (>3 nuclei) were
more prominent in the joints of control CAIA mice than
in the joints of mice in the ASC pre and ASC post
groups (Fig. 2d). The number and area of osteoclasts
were higher in the joints of control CAIA mice than in
the joints of mice in the ASC pre and ASC post groups
(Fig. 2e and f).
Serum levels of TNFα, IL-15, resistin, and leptin are de-
creased in ASC-injected mice
To understand the mechanism underlying the effects of
ASCs on CAIA, we examined the serum levels of five
cytokines (IL-15, IL-1α, IL-6, IL-7, and TNFα), five
diabetes-related hormones (resistin, GIP, GLP-1, ghrelin,
and leptin), and adiponectin using multiplex immunoas-
says. The serum levels of IL-15, resistin, and leptin were
decreased in the ASC pre and ASC post groups (Fig. 3d,
e, and f ). The serum level of TNFα was reduced in the
ASC pre group, but not in the ASC post group (Fig. 3a).
IL-6 and adiponectin did not significantly differ among
the experimental groups (Fig. 3b and c).
ASCs induce the over-expression of Fc gamma receptors
(FCGRs) in peritoneal cells
T-cells and B-cells are rarely involved in disease patho-
genesis in CAIA models; therefore, the immune complex
is regarded as a potential player in this system. The im-
mune complex usually signals via FCGRs. The relationship
between FCGRs and stem cells has not been explored. The
mRNA levels of FCGRs found on macrophages were inves-
tigated. Peritoneal cells of ASC-injected mice expressed
FCGRI, FCGRIIB, and FCGRIII (Fig. 4a). Expression of
FCGRIIB, which is a well-known anti-inflammatory signal
mediator, was higher than that of FCGRI (Fig. 4b).
The conditioned media of ASCs induces the over-
expression of FCGRI and FCGRIIB in macrophages
To simulate the effects of ASCs on FCGRs, ASCs and
RAW264.7 cells were co-cultured. Co-culture with ASCs
increased the expression of FCGRI and FCGRIIB in a
time-dependent manner (Fig. 5a). Although FCGRI ex-
pression increased concomitant with that of FCGRIIB,
expression of FCGRIIB increased more than expression
of FCGRI, which has a pro-inflammatory role (Fig. 5b).
The conditioned media of ASCs increased expression
of FCGRI and FCGRIIB in RAW264.7 cells (Fig. 5c).
FCGRI and FCGRIIB levels were highest at 12 hr after
stimulation with this conditioned media. Thereafter,
expression of FCGRs decreased in a time-dependent
manner. In conclusion, expression of FCGRI and
FCGRIIB on macrophages was associated with ASCs or
ASC-secreted molecules. The higher expression of
FCGRIIB than of FCGRI is an interesting phenomenon
that may be linked with the anti-inflammatory properties
of ASCs (Fig. 5d).
Discussion
The present study demonstrates that human ASCs can
induce expression of inhibitory FCGRs on macrophages
in CAIA mice. This is a novel mechanism via which
ASCs elicit immunosuppressive effects.
There are several mechanisms through which ASCs
suppress immunity. ASCs secrete transforming growth
factor β1, a growth factor that promotes premature im-
mune tolerance [8]. Furthermore, ASC treatment in-
creases expression of IL-10, which might enhance T-reg
function, in mice with experimental colitis. In vitro,
human ASCs suppress the collagen-specific response of
T-cells from patients with RA. Human ASCs inhibit the
proliferative response of collagen-activated T-cells, as
well as the production of inflammatory cytokines by
these cells, and increase the number of IL-10-producing
T-cells and monocytes. Human ASCs also stimulate the
generation of T-reg [23]. Human ASCs have immuno-
suppressive effects in CIA mice [16, 18]. Systemic infu-
sion of human ASCs reduces the incidence and severity
of CIA, decreases collagen-specific Th1/Th17 cell differ-
entiation, and induces T-reg generation.
CIA is an immunologically mediated disease involving
T-cells, B-cells, and inflammatory cells that infiltrate
joints, whereas CAIA is a T-cell- and B-cell-independent
arthritis model [21]. In the present study, ASC treatment
in CAIA mice significantly decreased the severity of arth-
ritis, but had little effect on the Th17/T-reg balance, which
is a mechanism via which ASCs elicit anti-arthritic effects
in CIA. This may be related to the T-cell-independent
characteristic of CAIA. Our data elicited a novel mechan-
ism in which ASCs elicit immunomodulatory effects by
regulating FCGRs.
FCGRs play a crucial role in antibody-mediated auto-
immune diseases. FCGRs can mediate various functions,
such as antibody-dependent cellular cytotoxicity and
phagocytosis. FCGRs are considered to be important im-
mune regulators linked to autoimmunity. The actions of
FCGRs are mediated by activating and inhibitory receptors
that bind to the same Fc portion of IgG. FCGRI and
FCGRIII are activating receptors. FCGRIIb1 and FCGRIIb2
contain an immunoreceptor tyrosine-based inhibition
motif that is responsible for mediating inhibitory, rather
than activating, functions [24].
FCGRIIB is widely expressed on cells of the innate im-
mune system, including mast cells, eosinophils, basophils,
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monocytes, neutrophils, dendritic cells, and macrophages.
FCGRIIB can modulate the activities of innate immune ef-
fector cells [25]. Inhibitory FCGRIIB contributes to immune
protection in two ways: (1) by down-regulating effector cell
responses, and (2) by maintaining peripheral tolerance [26].
In RA, the balance between activating and inhibitory
FCGR signaling controls inflammation and tissue damage
[27, 28]. FCGRIIB-deficient mice display a strongly
augmented IgG anti-collagen II humoral response that
causes a more severe arthritis phenotype than that ob-
served in control mice [29]. Antibodies mediate pro- and
anti-inflammatory activities via engagement of their Fc
fragment with FCGRs. Mice lacking the common FCGR
chain are highly resistant to CAIA. The absence of
FCGRIIB in mice exacerbates arthritis [30]. Expression of
FCGRs is dysregulated in macrophages of arthritic mice;
(See figure on previous page.)
Fig. 2 Injection of adipose-derived mesenchymal stem cells (ASCs) prevents inflammation and bone destruction. Collagen antibody-induced arthritis
(CAIA) mice were injected with ASCs three times every other day starting 3 days prior to (ASC pre group) or 4 days after (ASC post group)
immunization with an anti-collagen type II antibody. As controls, wild-type mice were injected with saline (WT group) and CAIA mice were similarly
immunized but not injected with ASCs (CAIA group). Each group comprised five mice. a Hind limbs were histologically evaluated by staining with
hematoxylin and eosin (H&E; scale bar, 400 μm) or toluidine blue (scale bar, 200 μm) at 14 days after immunization. From this, the inflammation score
(b) and joint destruction score (c) were determined. d Hind limbs were histologically evaluated by staining with TRAP at 14 days after immunization.
From this, the percentage of TRAP-positive cells (e) and the area of these cells (f) were determined. All quantitative data show the mean ± standard
error of the mean. *** p < 0.001 using Student’s t-test
Fig. 3 Serum levels of various cytokines/hormones are reduced in adipose-derived mesenchymal stem cell (ASC)-injected mice. Collagen
antibody-induced arthritis (CAIA) mice were injected with ASCs three times every other day starting 3 days prior to (ASC pre group) or 4 days
after (ASC post group) immunization with an anti-collagen type II antibody. As controls, wild-type mice were injected with saline (WT group)
and CAIA mice were similarly immunized but not injected with ASCs (CAIA group). Each group comprised five mice. Serum levels of tumor
necrosis factor α (TNFα, a), interleukin (IL)-6 b, adiponectin c, IL-15 d, resistin e, and leptin (f) were evaluated using multiplex immunoassays at
14 days after immunization, the day on which mice were sacrificed. Data show the mean ± standard error of the mean. * p < 0.05, ** p < 0.01,
and *** p < 0.001 using Student’s t-test
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expression of activating FCGRI and FCGRIII are pro-
longed and expression of inhibitory FCGRII is down-
regulated, resulting in chronic inflammation and severe
cartilage destruction [27].
Our data suggest that ASCs elicit inhibitory effects on
autoimmune arthritis by controlling FCGR expression
on macrophages. Inhibition of macrophages by ASCs
reduced the secretion of inflammatory cytokines, such as
IL-15, IL-6, and TNF-α. IL-15 is a pro-inflammatory
cytokine that is over-expressed in RA and is produced
by differentiated macrophages, dendritic cells, and bone
marrow stromal cells [31]. IL-6 and TNF-α are well-
known pro-inflammatory cytokines that are important to
the pathogenesis of RA. Suppression of these pro-
Fig. 4 Adipose-derived mesenchymal stem cells (ASCs) increase expression of Fc gamma receptors (FCGRs) in peritoneal cells. Collagen
antibody-induced arthritis (CAIA) mice were injected with ASCs three times every other day starting 3 days prior to (ASC pre group) or
4 days after (ASC post group) immunization with an anti-collagen type II antibody. As controls, wild-type mice were injected with saline
(WT group) and CAIA mice were similarly immunized but not injected with ASCs (CAIA group). Each group comprised 5 mice. Peritoneal
cells were isolated at sacrifice time. Total RNA was extracted from these cells and reverse-transcription PCR was performed with primers
designed to amplify FCGRI, FCGRIIB, FCGRIII, and GAPDH (a). The intensities of the bands, relative to those of GAPDH, were determined
(b, mean ± standard error of the mean)
Fig. 5 Adipose-derived mesenchymal stem cell (ASCs) conditioned media increases Fc gamma receptor (FCGR) expression in macrophages. RAW264.7
murine macrophages were co-cultured with commercially purchased ASCs (a and b) or with the conditioned media of these cells (ASC-CM, c and d)
for various numbers of hours. Total RNA was extracted from the cells and reverse-transcription PCR was performed with primers designed to amplify
FCGRI, FCGRIIB, FCGRIII, and GAPDH (a and c). The intensities of the bands, relative to those of GAPDH, were determined (b and d, mean ± standard
error of the mean)
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inflammatory cytokines by ASCs decreased the severity
of arthritis in mice. This is the first report of the inhibi-
tory effect of ASCs on CAIA via increased expression of
FCGRIIB. However, the mechanisms underlying the in-
duction of FCGRs by ASCs were not addressed in this
study. It remains to be established whether ASCs act dir-
ectly on FCGR expression.
The results of the present study suggest that treatment
with ASCs did not increase the serum levels of pro-
inflammatory adipokines. The expression of most pro-
inflammatory adipokines, including leptin, is increased in
obesity and this contributes to a “low grade inflammatory
state”, which causes a variety of metabolic aberrations that
affect joints and bone [32]. Leptin is an adipokine with
pleiotropic actions that regulate food intake, energy me-
tabolism, inflammation, and immunity [33]. A recent
study reported that leptin is involved in promoting the
pathogenesis, development, and/or progression of RA
[34]. Resistin is also associated with increased inflamma-
tion and joint destruction in RA patients [22]. Although
ASCs reduced the severity of arthritis, they could poten-
tially cause chronic inflammation if they increase the gen-
eration of pro-inflammatory adipokines in vivo. Our data
showed that ASCs attenuate arthritis without increasing
the serum levels of adipokines.
Conclusions
In summary, the present study shows for the first time
that human ASCs attenuate autoimmune arthritis in
CAIA. They induce the expression of inhibitory FCGRs
on macrophages and inhibit the secretion of pro-
inflammatory cytokines without affecting the serum
levels of pro-inflammatory adipokines. The regulation
of FCGRIIB by ASC treatment will be the focus of
therapeutic approaches to treat RA.
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